Justina Petrullo

Reference bevacizumab and proposed biosimilar (BAT1706) demonstrate high similarity to each other.

Here are the top 5 biosimilar articles for the week of July 17, 2023.

Biosimilars may be able to increase treatment access for traditionally excluded communities, especially racial and ethnic minority populations.

Here are the top 5 biosimilar articles for the week of July 10, 2023.

Multiple real-world infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort study.

Noninferiority and comparable safety and immunogenicity between biosimilar romiplostim (ENZ110) and innovator romiplostim (Nplate) were identified in patients with chronic immune thrombocytopenia.

Here are the top 5 biosimilar articles for the week of July 3, 2023.

The US gains 2 more adalimumab biosimilars on the market: Fresenius Kabi's Idacio (adalimumab-aacf) and Biocon Biologic's Hulio (adalimumab-fkjp). The launches come after 5 launched over the Fourth of July weekend.

Long-term results comparing ranibizumab biosimilar SB11 vs reference ranibizumab (Lucentis) on neovascular age-related macular degeneration (nAMD) support biosimilarity between the treatments.

On this episode, we’re going to be recapping some of the biggest stories in the business space regarding biosimilars, including adalimumab preparation, partnerships for commercialization, and more.

Here are the top 5 biosimilar articles for the week of June 26, 2023.

It was found that cancer treatment, pediatric population, and coverage restriction of reference products were revealed as some of the strongest factors associated with biosimilar coverage decisions by US commercial health plans relative to reference products.

Here are the top 5 biosimilar articles for the week of June 19, 2023.

Enhancing pharmacists’ knowledge of biosimilars can assist in promoting their use and defeat misconceptions and misinformation related to generic drugs and biosimilars.

Here are the top 5 biosimilar articles for the week of June 12, 2023.

Infliximab (IFX) biosimilar SB2 was shown to be safe and effective in IFX-naïve patients and those who switched from a prior IFX reference or biosimilar.

Here are the top 5 biosimilar articles for the week of June 5, 2023.

If biosimilars are introduced to Spain, they will most likely save money in the pharmacological budget, according to a budget impact analysis model.

On this episode of Not So Different, we recap some of the biggest stories in the immunology space regarding biosimilars, including a new European approval, ustekinumab biosimilar delays, and more.

Here are the top 5 biosimilar articles for the week of May 29, 2023.

Here are the top 5 biosimilar articles for the week of May 22, 2023.

Findings from a recent study emphasize the need for improvement and changes regarding follow-on biologics and biosimilars in the global biosimilar market.

Here are the top 5 biosimilar articles for the week of May 15, 2023.

Here are the top 5 biosimilar articles for the week of May 8, 2023.

Here are the top 5 biosimilar articles for the week of May 1, 2023.

Biosimilar ranibizumab showed similar efficacy and safety in a recent study of the eyes of Indian patients with neovascular age-related macular degeneration.

A recent systematic review looked at the impact of different prices for infliximab in inflammatory bowel disease and the willingness-to-pay threshold around the world.

Here are the top 5 biosimilar articles for the week of April 17, 2023.

A retrospective study in Scotland found that multiple successive changes from originator infliximab to biosimilars seem to be safe and effective in patients with inflammatory bowel disease (IBD), irrespective of the number of switches.

Here are the top 5 biosimilar articles for the week of April 10, 2023.